- Lobbying
- Lobbying by WCG Clinical, Inc.
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Michael Gaffin | Leg. Director, Sen. Sherrod Brown; Leg. Director, Rep. Rob Andrews; Leg. Asst., Rep. Anna Eshoo; Jr. Leg. Assoc., House Ed. and Labor Committee, Rep. George Miller; Staff Assist, Senate HELP Committee, Sen. Edward Kennedy Leg. Director, Sen. Sherrod Brown; Leg. Director, Rep. Rob Andrews; Leg. Asst., Rep. Anna Eshoo; Jr. Leg. Assoc., House Ed. and Labor Committee, Rep. George Miller; Staff Assist, Senate HELP Committee, Sen. Edward Kennedy |
Jack S. Deuser | Ch. of Staff, U.S. Sen. Jim Bunning Ch. of Staff, U.S. Sen. Jim Bunning |
Trevor Kolego | Leg. Assist, Rep. Chris Cannon; Leg. Director, Rep. Jon Porter; Manager of Member Services, Leader John Boehner; Director of Member Services, Speaker John Boehner Leg. Assist, Rep. Chris Cannon; Leg. Director, Rep. Jon Porter; Manager of Member Services, Leader John Boehner; Director of Member Services, Speaker John Boehner |
Sarah Dumont-Merchak | Director of Congressional Affairs, Federal Housing Finance Agency; Professional Staff Member, Senate Banking Committee. |
Robert W. Hickmott | n/a |
W. Timothy Locke | n/a |
James C. Free | n/a |
Michael A. Gaffin | n/a |
Michael A Gaffin | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q4 Report
Q3 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Amendment
Lobbying Issues
Agencies Lobbied
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Registration
Issue(s) they said they’d lobby about: Issues related to clinical trials..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate